Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2025)

C4 Therapeutics' Depreciation and Depletion history spans 6 years, with the latest figure at $377000.0 for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 3.57% year-over-year to $377000.0; the TTM value through Dec 2025 reached $1.5 million, up 10.07%, while the annual FY2025 figure was $1.5 million, 4.62% up from the prior year.
  • Depreciation and Depletion reached $377000.0 in Q4 2025 per CCCC's latest filing, down from $384000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $521000.0 in Q4 2022 to a low of $128000.0 in Q4 2023.
  • Average Depreciation and Depletion over 5 years is $382100.0, with a median of $380500.0 recorded in 2025.
  • Peak YoY movement for Depreciation and Depletion: tumbled 75.43% in 2023, then soared 184.38% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $323000.0 in 2021, then soared by 61.3% to $521000.0 in 2022, then crashed by 75.43% to $128000.0 in 2023, then skyrocketed by 184.38% to $364000.0 in 2024, then rose by 3.57% to $377000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Depreciation and Depletion are $377000.0 (Q4 2025), $384000.0 (Q3 2025), and $416000.0 (Q2 2025).